A Phase 4 interventional study of CYPHERTM Sirolimus-Eluting Coronary Stent in Coronary Artery Disease, sponsored by Cordis Corporation. Completed. Per ClinicalTrials.gov, last updated 2007-04-04.
Sponsored by Cordis Corporation · Phase 4, Interventional, and Treatment
The purpose of this PMS registry, named e-CYPHER Stent Registry, is to collect post marketing surveillance data on the CYPHERTM Sirolimus-eluting Coronary Stent following marketing approval, when used in normal clinical practice within the labeled indications.
5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.
This study's enrollment of 2,070 is above the median of 124 across 3,436 interventional studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Cordis Corporation is the lead sponsor of 70 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
MACE at 30 days, 6 months and 1 year.
There is no pre-specified secondary outcome.
No study locations are listed for this record.
This study is completed, as verified in Apr 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cordis Corporation